Sernova Corp
TSX VENTURE : SVA

Sernova Corp

March 25, 2008 09:30 ET

Sernova Corp.: Islet Cell Pioneer Appointed to Help Advance Sertolin Diabetes Therapy

KELOWNA, BRITISH COLUMBIA--(Marketwire - March 25, 2008) - Sernova Corp. ("Sernova") (TSX VENTURE:SVA) is pleased to announce that world class, pancreatic islet transplant expert, Dr. Shinichi Matsumoto, Director of the Baylor All Saints Islet Cell Laboratory at the Baylor Research Institute in Fort Worth Texas, has accepted an appointment to Sernova's Scientific Advisory Board (SAB). Dr. Matsumoto is a pioneer in human islet transplantation to treat diabetics. He has many notable accomplishments in the field of islet transplantation, which will assist Sernova in pursuing its clinical regulatory path going forward. His research has resulted in numerous scientific publications on islet isolation, preparation and transplantation.

"With his knowledge of the intricacies of islet biology and islet transplants, Dr. Matsumoto is a key addition to our SAB and Sernova's diabetes therapy research," commented Dr. David White, Sernova's Principal Researcher. "His expertise in islets complements well that of the other SAB members who are experts in diabetes, immunology, and Sertoli cells."

About Dr. Matsumoto

Dr. Matsumoto is currently the Director of the Baylor All Saints Islet Cell Laboratory, and the Islet Cell Transplantation Laboratory at the Baylor Research Institute. Dr. Matsumoto graduated from medical school in 1988 and received his postgraduate training in 1996 from Kobe University School of Medicine in Kobe, Japan. He is board certified in surgery and gastroenterological surgery. He joined the medical staff of Kobe University Hospital in 1996. From 1997 to 2002, Matsumoto studied at islet transplant centers in Minneapolis and Seattle. Dr. Matsumoto joined Northwest Tissue Center (Seattle) in 2000, as senior research scientist in Human Islet Transplantation and consultant to the Human Islet Processing Facility. Just prior to joining Baylor he served as assistant professor at Kyoto University Hospital Transplantation Unit and as Director of the Diabetes Research Institute in Kyoto.

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

Justin Leushner, President

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information